PLOD1作为胶质瘤潜在预后标志物的临床价值研究

打开文本图片集

AbstractObective：ToExploretheexpresionlevelprognosticvalue，andaspotentialprogosticmarkerandtherapeticagetf procollagen-lsinxoutaratedoygenaseO）iiauingpublicdatabaes.Methds：Prognosticesatedtoi intheCGGAdatabaseandGEOdatabasewerescreened.Theintersectionofthetwoselectedgenesets，secondaryfileringinthe GEPIA databasewasperformedtoultimatelyobtainthetargetgenes.Prognosticanalysisofthetargetgene wasconductedinthetwo datasetsrespectivelySubsequentlaprognosticnmogramwasconstructedanditsaccuracyasverfiedThenrichmentanalysisas performed，threbyarfyingthattesegenesmightinvoleinimmunefunctionBasedonthisbsismmuneinflratioaalyisco expressionanalysisandextealvalidationwerefinallyconducted.Resuls：Thefinaltargetgeneidentfedforgliomaprognosisas PLOD1.Theresulsofsurvivalanalyss，receiveroperatingcharacterstic（OC）curve，and independentprognosticanalysissowdthat PLOD1 with beter predictive valueandcouldbeusedasaprognostic geneforgioma.Meanwhile，clinicalcorelationanalysis inthe CGGAdatabasesuggestedthatPwascorrelatedwithutileclinicalfeaturesSubsequentlyaprognosticcolumnchartmprising sevenindependentprognosticfactorsderivedfromtheCGGAdatabasewasconstructedandvalidatedusingcalibrationcurvesandROC cures.Theenrichmentfunctionandpathwayanalysisresults indicatedthatPLOD1notonlyplayedakeyroleinthebiosynthesisand cross-inkingflslsadsiologicldpathoialprocesiditracellaricral remodeling，butalsowassignificantlyenrichedinimmunerelatedsigalingpathways，includingtecomplementandcoagltion cascadesantigenproessingndpresentationdep5signainpatayedotedatabasetereseio betweenPLOD1andimmuneinfitratingcelsinglioma.Teextemalvalidationof HPAdatabasealsosupportedtheaboveviewpoint.

Conclusion：PODisgexpressedingioaanditsgxpresiocanseeasanindependentprogosticfactoforprprosis inglioma;PLOD1afectstheprogressonofgliomathroughmuitipleimmunerelatedmolecularpathwaysandmaybeapotential immunotherapytarget forglioma.

Keywordsglioma;procollagen-lysine，2-oxoglutarate5-dioxygenase（POD1）;prognosis; immunity;biomarkers

神经胶质瘤占颅内恶性肿瘤的 80% 左右，是颅内最常见的原发性恶性肿瘤1，依据世界卫生组织（WHO）对胶质瘤的分级标准，1、2级为低级别胶质瘤（low-gradeglioma，LGG），3、4级为高级别胶质瘤（high-gradeglioma，HGG）。（剩余15957字）